表紙
市場調查報告書

青光眼:開發平台分析

Glaucoma - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 232844
出版日期 內容資訊 英文 340 Pages
訂單完成後即時交付
價格
Back to Top
青光眼:開發平台分析 Glaucoma - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 340 Pages
簡介

本報告提供青光眼的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新新聞及發表的企業和研究機關開發中的治療藥、治療藥評估、後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

青光眼概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

青光眼:企業開發中的治療藥

青光眼:大學/機關研究中的治療藥

青光眼:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

青光眼:企業開發中的產品

青光眼:大學/機關研究中的產品

青光眼的治療藥的開發企業

  • AC Immune SA
  • Acadia Pharmaceuticals Inc.
  • Advanced Refractive Technologies, Inc.
  • Aerie Pharmaceuticals, Inc.
  • Allergan Plc
  • Altacor Limited
  • Amakem NV
  • Amarantus Bioscience Holdings, Inc.
  • Astellas Pharma Inc.
  • AUS Bio Limited
  • Bausch & Lomb Incorporated
  • BioAxone BioSciences, Inc.
  • Bionure Farma, S.L.
  • Caladrius Biosciences, Inc.
  • Can-Fite BioPharma Ltd.
  • Coronis Partners Ltd.
  • D. Western Therapeutics Institute, Inc.
  • Dompe Farmaceutici S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • Gene Signal International SA
  • Gilead Sciences, Inc.
  • Glaukos Corporation
  • GliaCure Inc.
  • Handok Inc.
  • Icon Bioscience, Inc.
  • ID Pharma Co., Ltd.
  • InMed Pharmaceuticals Inc.
  • Inotek Pharmaceuticals Corporation
  • InSite Vision Incorporated
  • Isarna Therapeutics GmbH
  • Kadmon Corporation, LLC
  • Kala Pharmaceuticals, Inc.
  • 興和
  • Kukje Pharmaceutical Industry Co., Ltd.
  • Lee's Pharmaceutical Holdings Limited
  • Lexicon Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Merz Pharma GmbH & Co. KgaA
  • Nemus Bioscience, Inc.
  • Neurotech Pharmaceuticals, Inc.
  • NicOx S.A.
  • NoNO, Inc.
  • Novaliq GmbH
  • Ocular Therapeutix, Inc.
  • Oculis ehf
  • Ohr Pharmaceutical Inc.
  • 小野藥品工業
  • 大塚集團
  • Oxford BioMedica Plc
  • pSivida Corp.
  • Quark Pharmaceuticals, Inc.
  • Quethera Limited
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • 參天製藥
  • 千壽製藥
  • Shire Plc
  • SK Biopharmaceuticals Co., Ltd.
  • Sun Pharma Advanced Research Company Ltd.
  • Sylentis S.A.U.
  • UAB Profarma
  • ViSci Ltd.
  • vTv Therapeutics LLC

青光眼:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

青光眼:最近的開發平台趨勢

青光眼:暫停中的計劃

青光眼:開發中止的產品

青光眼:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11478IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glaucoma - Pipeline Review, H2 2019, provides an overview of the Glaucoma (Ophthalmology) pipeline landscape.

Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glaucoma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Glaucoma (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glaucoma (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 12, 18, 10, 3, 67, 14 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 3 molecules, respectively.

Glaucoma (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glaucoma (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Glaucoma (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glaucoma (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glaucoma (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glaucoma (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glaucoma (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glaucoma (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Glaucoma - Overview
  • Glaucoma - Therapeutics Development
  • Glaucoma - Therapeutics Assessment
  • Glaucoma - Companies Involved in Therapeutics Development
  • Glaucoma - Drug Profiles
  • Glaucoma - Dormant Projects
  • Glaucoma - Discontinued Products
  • Glaucoma - Product Development Milestones
  • Appendix

List of Tables

  • Table 1: Number of Products under Development for Glaucoma, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Table 7: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 8: Products under Development by Companies, H2 2019
  • Table 9: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 10: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 11: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 12: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Table 13: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Table 14: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Table 15: Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Table 16: Products under Development by Universities/Institutes, H2 2019
  • Table 17: Number of Products by Stage and Target, H2 2019
  • Table 18: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Table 19: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Table 20: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
  • Table 21: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 22: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Table 23: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Table 24: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
  • Table 25: Number of Products by Stage and Route of Administration, H2 2019
  • Table 26: Number of Products by Stage and Molecule Type, H2 2019
  • Table 27: Glaucoma - Pipeline by AC Immune SA, H2 2019
  • Table 28: Glaucoma - Pipeline by Acorn Biomedical Inc, H2 2019
  • Table 29: Glaucoma - Pipeline by Aerie Pharmaceuticals Inc, H2 2019
  • Table 30: Glaucoma - Pipeline by Aerpio Pharmaceuticals Inc, H2 2019
  • Table 31: Glaucoma - Pipeline by Allergan Plc, H2 2019
  • Table 32: Glaucoma - Pipeline by Amarantus Bioscience Holdings Inc, H2 2019
  • Table 33: Glaucoma - Pipeline by Amgen Inc, H2 2019
  • Table 34: Glaucoma - Pipeline by Annexon Inc, H2 2019
  • Table 35: Glaucoma - Pipeline by Ascentage Pharma Group International, H2 2019
  • Table 36: Glaucoma - Pipeline by Asha Vision LLC, H2 2019
  • Table 37: Glaucoma - Pipeline by Betaliq Inc, H2 2019
  • Table 38: Glaucoma - Pipeline by Bial - Portela & Ca SA, H2 2019
  • Table 39: Glaucoma - Pipeline by BioAxone BioSciences Inc, H2 2019
  • Table 40: Glaucoma - Pipeline by Califia Bio Inc, H2 2019
  • Table 41: Glaucoma - Pipeline by Calpain Therapeutics Pty Ltd, H2 2019
  • Table 42: Glaucoma - Pipeline by Cellix Bio Pvt Ltd, H2 2019
  • Table 43: Glaucoma - Pipeline by Certa Therapeutics Pty Ltd, H2 2019
  • Table 44: Glaucoma - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019
  • Table 45: Glaucoma - Pipeline by D. Western Therapeutics Institute Inc, H2 2019
  • Table 46: Glaucoma - Pipeline by Deha Pharmaceutical LLC, H2 2019
  • Table 47: Glaucoma - Pipeline by Dhp Korea Ltd, H2 2019
  • Table 48: Glaucoma - Pipeline by Disarm Therapeutics Inc, H2 2019
  • Table 49: Glaucoma - Pipeline by Dompe Farmaceutici SpA, H2 2019
  • Table 50: Glaucoma - Pipeline by Emerald Bioscience Inc, H2 2019
  • Table 51: Glaucoma - Pipeline by Envisia Therapeutics Inc, H2 2019
  • Table 52: Glaucoma - Pipeline by Evotec SE, H2 2019
  • Table 53: Glaucoma - Pipeline by Eyenovia Inc, H2 2019
  • Table 54: Glaucoma - Pipeline by EyePoint Pharmaceuticals Inc, H2 2019
  • Table 55: Glaucoma - Pipeline by Eyevensys SAS, H2 2019
  • Table 56: Glaucoma - Pipeline by Fortress Biotech Inc, H2 2019
  • Table 57: Glaucoma - Pipeline by Future Medicine Co Ltd, H2 2019
  • Table 58: Glaucoma - Pipeline by Galimedix Therapeutics Ltd, H2 2019
  • Table 59: Glaucoma - Pipeline by Gene Signal International SA, H2 2019
  • Table 60: Glaucoma - Pipeline by Glaukos Corp, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Glaucoma, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Top 10 Targets, H2 2019
  • Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top